Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:363 |
Name | uterine cancer |
Definition | A female reproductive organ cancer that is located_in the uterus. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4363 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN mutant | GSK2256098 | uterine cancer | sensitive | detail... |
PTEN wild-type | GSK2256098 | uterine cancer | decreased response | detail... |
PTEN mutant | GSK2256098 + Paclitaxel | uterine cancer | sensitive | detail... |
PTEN mutant | GSK2256098 + Topotecan | uterine cancer | sensitive | detail... |
PIK3CA I391M | Sirolimus | uterine cancer | predicted - sensitive | detail... |
FGFR2 amp | Zoligratinib | uterine cancer | predicted - sensitive | detail... |
HRAS Q61H | BTX-6654 | uterine cancer | sensitive | detail... |
HRAS Q61H | BTX-7312 | uterine cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Unknown status | USA | 0 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Active, not recruiting | USA | ITA | GBR | ESP | 2 |
NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
NCT02874430 | Phase II | Doxycycline + Metformin | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | Unknown status | USA | 0 |
NCT03206177 | Phase I | Carboplatin + Galunisertib + Paclitaxel | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | Completed | USA | 0 |
NCT03241745 | Phase II | Nivolumab | A Study of Nivolumab in Selected Uterine Cancer Patients | Completed | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
NCT04493619 | Phase Ib/II | Carboplatin + PLX2853 PLX2853 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Terminated | USA | CAN | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT05180474 | Phase Ib/II | GEN1047 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | BEL | 0 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05800964 | Phase I | AMG 305 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT06107868 | Phase I | Carboplatin + Paclitaxel + RP-6306 | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (GyneRep) | Active, not recruiting | CAN | 0 |
NCT06130254 | Phase I | Adagrasib + Olaparib | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Recruiting | USA | 0 |
NCT06180733 | Phase II | Pembrolizumab | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II) | Recruiting | NLD | 0 |
NCT06276491 | Phase I | XmAb541 | Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06389123 | Phase I | 177Lu-DOTA-ABM-5G | Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas | Recruiting | USA | 0 |